The “All-In on America” trade is showing cracks. Ashmore Group, the specialist Emerging Markets asset manager, reported a standout quarter with $2.6 billion in net inflows and $1.2 billion in positive investment performance, signaling a tangible shift in allocator sentiment. 📊 THE NUMBERS (Q2 ended Dec 31, 2025): ⚠️ THE US CONCENTRATION RISK: Ashmore didn’t...
🌏 PRIVATE CREDIT RECORD: KKR Closes $2.5B for Largest Asia Performing Credit Fund
The “Golden Age of Private Credit” is officially going global. KKR announced today the final close of its second Asia-focused credit vehicle, securing $2.5 billion in total commitments. This makes it the largest pan-regional fund dedicated to performing private credit in Asia-Pacific history. 💰 THE FUNDRAISE BREAKDOWN: 🎯 THE STRATEGY: Unlike distressed funds that hunt...
🇮🇹 ITALIAN ASSET MANAGEMENT BOOM: Inflows Surge 47% to €68 Billion
While European asset managers struggle to defend market share against US giants, Italy’s listed players are posting record numbers. Italy’s top five listed asset gatherers reported combined net inflows of €68 billion ($79 billion) for 2025, a stunning 46.8% increase year-over-year. 🚀 THE DECEMBER SPIKE: December was an outlier month, with inflows hitting €18.2 billion...
🏦 EARNINGS RECAP: Loan Growth Surges at Big Banks, but Policy Clouds Loom
The US economy is borrowing again. Major US banks reported strong Q4 results today, driven not just by high rates, but by a tangible pickup in loan demand from both businesses and consumers. 📈 THE GROWTH ENGINE: Despite fears of a slowdown, the “Big Four” are seeing credit expansion accelerate: 🗣️ THE “REAL” ECONOMY VIEW:...
🎬 MEDIA WARS: Netflix Preps “All-Cash” Bid for Warner Bros to Knock Out Paramount
The battle for the “Harry Potter” and “Game of Thrones” libraries just went nuclear. Sources report that Netflix (NFLX) is preparing to revise its $82.7 billion offer for Warner Bros Discovery’s (WBD) studio and streaming assets to all-cash, aiming to expedite the sale and eliminate the execution risk associated with its previous cash-and-stock bid. 🥊...
🧬 BIOTECH REBOUND: Sector Poised for 2026 Comeback as IPO Window Reopens
After hitting a decade-low in 2025, the US biotech sector is flashing buy signals again. Analysts and investors are forecasting a robust rebound in 2026, driven by a stabilizing policy environment, lower interest rates, and a backlog of mature private companies ready to test the public markets. 📉 THE 2025 BOTTOM: 🌤️ THE 2026 OUTLOOK:...
